USD 0.3
(-6.91%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -70.57 Million USD | -162.69% |
2022 | -26.86 Million USD | -7.16% |
2021 | -25.07 Million USD | 30.45% |
2020 | -36.04 Million USD | 36.72% |
2019 | -56.95 Million USD | -84.73% |
2018 | -30.83 Million USD | -73.55% |
2017 | -17.76 Million USD | -322.77% |
2016 | -4.2 Million USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -2.67 Million USD | -299.85% |
2024 Q2 | -4.22 Million USD | -57.76% |
2023 Q2 | -1.57 Million USD | 97.63% |
2023 Q1 | -66.4 Million USD | -713.83% |
2023 FY | -70.57 Million USD | -162.69% |
2023 Q4 | -669 Thousand USD | 65.28% |
2023 Q3 | -1.92 Million USD | -22.27% |
2022 Q1 | -5.49 Million USD | 33.69% |
2022 FY | -26.86 Million USD | -7.16% |
2022 Q4 | -8.15 Million USD | -71.3% |
2022 Q3 | -4.76 Million USD | 43.62% |
2022 Q2 | -8.44 Million USD | -53.74% |
2021 Q2 | -5.24 Million USD | 27.46% |
2021 Q4 | -8.28 Million USD | -92.81% |
2021 FY | -25.07 Million USD | 30.45% |
2021 Q3 | -4.29 Million USD | 18.12% |
2021 Q1 | -7.23 Million USD | 30.72% |
2020 FY | -36.04 Million USD | 36.72% |
2020 Q2 | -10.12 Million USD | -31.42% |
2020 Q4 | -10.44 Million USD | -34.26% |
2020 Q3 | -7.77 Million USD | 23.14% |
2020 Q1 | -7.7 Million USD | 20.96% |
2019 Q3 | -17.41 Million USD | -15.18% |
2019 Q2 | -15.12 Million USD | -3.05% |
2019 Q1 | -14.67 Million USD | 1.76% |
2019 FY | -56.95 Million USD | -84.73% |
2019 Q4 | -9.74 Million USD | 44.06% |
2018 Q2 | -8.39 Million USD | -211.73% |
2018 FY | -30.83 Million USD | -73.55% |
2018 Q4 | -14.93 Million USD | -210.73% |
2018 Q1 | -2.69 Million USD | 13.02% |
2018 Q3 | -4.8 Million USD | 42.74% |
2017 Q4 | -3.09 Million USD | -80.0% |
2017 Q2 | -11.28 Million USD | -579.0% |
2017 Q1 | -1.66 Million USD | 0.0% |
2017 Q3 | -1.72 Million USD | 84.76% |
2017 FY | -17.76 Million USD | -322.77% |
2016 FY | -4.2 Million USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Perspective Therapeutics, Inc. | -14.67 Million USD | -381.063% |
Electromed, Inc. | 5.15 Million USD | 1470.33% |
Senseonics Holdings, Inc. | -60.39 Million USD | -16.857% |
Xtant Medical Holdings, Inc. | 660 Thousand USD | 10792.727% |